All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding our revenue results . LEXINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO ), a leader in the rapid detection of sepsis-causing pathogens, announced today plans to consolidate its . All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements . T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical . T2 Biosystems T2SARS-CoV-2 Panel Proves Capable of Detecting the Mu B.1.621 and Iota B.1.526 Variants of the SARS-CoV-2 Virus Globe Newswire 4:52 PM -- September 8, 2021 -- T2 Biosystems Announces Plans to Consolidate and Expand Facilities in Massachusetts Globe Newswire 5:20 PM 01/11/22. 02/04/22. T2 BIOSYSTEMS. Year. T2 Biosystems to Unveil New Data at September Conferences . Login . According to the Centers for Disease Control and Prevention, the Omicron variant of the SARS-CoV-2 virus now accounts for 99.9% of all COVID . This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. T2 Biosystems, Inc., a company developing the first portable medical diagnostic products which combine nanotechnology and miniaturized magnetic resonance (MR) technology, today announced the appointment of Pamela J. Weagraff, RAC to the newly created position of Vice President, Regulatory and Quality. T2 Biosystems Reports Granting of Inducement Award. LEXINGTON, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that its T2SARS-CoV-2™ Panel detects Omicron COVID-19 subvariants BA.1, BA.2, and BA.3. Latest Press Releases for T2 Biosystems CS (TTOO-Q). LEXINGTON, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced unaudited preliminary financial result estimates for the quarter ended June 30, 2020.In addition, the Company announced the U.S. launch of the T2SARS-CoV-2™ Panel, the . 01/11/22. LEXINGTON, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the initiation of a U.S. multi . Excerpt from the Press Release: LEXINGTON, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that its T2SARS-CoV-2™ Panel detects Omicron COVID-19 subvariants BA.1, BA.2, and BA.3. About T2 Biosystems . LEXINGTON, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial results for the fourth quarter and full year ended December 31, 2021. all statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding t2 biosystems' ability to advance its growth strategy, as well as statements that include the words "expect," "intend," "plan", "believe", "project", … About T2 Biosystems . Press release content from Globe Newswire. 02/03/22. T2 Biosystems, Inc. October 15, 2021 GMT. Shares +5.6%. T2 Biosystems to Report Fourth Quarter and Full Year 2021 Financial Results on February 17, 2022. LEXINGTON, Mass., Jan. 11, 2022(GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced preliminary unaudited financial and operational results for the fourth quarter and full year 2021. T2 Biosystems T2SARS-CoV-2™ Panel Detects Omicron Subvariants. LEXINGTON, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the initiation of a U.S. multi-site clinical trial evaluating the performance of its T2Resistance ® Panel designed to support a submission to the U.S. Food and Drug . LEXINGTON, Mass., Oct. 22, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial. We believe combining our collective expertise with T2 Biosystems' proprietary T2MR platform may enable us to develop a fully differentiated diagnostic panel for the detection of Lyme disease, an area of critical need where delays in providing appropriate treatment to patients can result in significant morbidity and unnecessary costs. T2 Biosystems Reports Granting of Inducement Award. T2 Biosystems Announces Commercial Expansion Through Distributors in Norway, Finland and Türkiye. The company expects FY2022 total revenue of $28M to . . This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the ability of T2's culture-independent diagnostics to improve the standard of care for patients at risk of sepsis and to expand in the Asia . . LEXINGTON, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the initation of a U.S. clinical trial evaluating the performance of its T2Biothreat® Panel designed to support a submission to . LEXINGTON, Mass., Oct. 15, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced . Start Now! About T2 Biosystems T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems Announces Third Quarter 2021 Financial Results. LEXINGTON, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. ( TTOO ), a leader in the rapid detection of sepsis-causing pathogens, today announced the completion of validation of its. T2 Biosystems Announces First Quarter 2021 Financial Results LEXINGTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the three months ended March 31, 2021. 02/03/22. T2 Biosystems OVERVIEW. LEXINGTON, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing . Revenue of $6.98M (-10.3% Y/Y) beats by $1.58M. T2 Biosystems T2SARS-CoV-2™ Panel Detects Omicron Subvariants. LEXINGTON, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the successful amendment and extension to its Term Loan Agreement with CRG Servicing LLC ("CRG"). T2 Biosystems T2SARS-CoV-2 Panel Proves Capable of Detecting the Mu B.1.621 and Iota B.1.526 Variants of the SARS-CoV-2 Virus Globe Newswire 4:52 PM -- September 8, 2021 -- T2 Biosystems Announces Plans to Consolidate and Expand Facilities in Massachusetts Globe Newswire 5:20 PM LEXINGTON, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a global leader in the rapid detection of sepsis-causing pathogens, today announced that its Board of Directors has appointed Aparna Ahuja, MD, as Chief Medical Officer (CMO), effective immediately. 02/08/22. LEXINGTON, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced . T2 Biosystems Announces Third Quarter 2021 Financial Results. Home . The amendment extends both the interest-only period and the maturity date by one year from December 31, 2022 to December 31, 2023. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most . Title. Full Year 2021 Total Revenue Growth of 55%; Plans to Double Sepsis Revenue and T2Dx Instruments. Launches the T2SARS-CoV-2™ Panel under FDA EUA Guidelines. LEXINGTON, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis . T2 Biosystems, Inc. Lexington, Massachusetts, UNITED STATES. Recent Highlights (unaudited) Achieved full year 2021 total revenue of $27.7 million, including product revenue of $16.7 million . Company Contact: John Sprague, T2 Biosystems Chief Financial Officer jsprague@t2biosystems.com 781-457-3898 LEXINGTON, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today reminded stockholders to vote at the upcoming 2021 Annual Meeting of Stockholders to be held on June 25, 2021.The T2 Biosystems Board of Directors unanimously supports each stockholder proposal on the proxy and encourages all stockholders to . Press Releases Keyword Search. In the News. T2 Biosystems press release (NASDAQ:TTOO): Q4 GAAP EPS of -$0.07 beats by $0.03. LEXINGTON, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the execution of territory exclusive distribution agreements in Singapore and South Korea. Achieved first quarter 2021 . The T2Biothreat (R) Panel, which runs on T2 Biosystems' T2Dx (R) Instrument, is a direct-from-blood test panel that provides results in 3-5 hours and simultaneously detects six biothreat pathogens. T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2021 Results. T2 Biosystems to Report First Quarter 2020 Financial Results on May 5, 2020 (News, TTOO, Press Releases / Tue, 04:22pm) Wednesday, April 15, 2020 T2 Biosystems Reports Granting of Inducement Award . T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2021 Results: 01/11/22. Shares +5.6%. January 11, 2022 - 9:00 am. LEXINGTON, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the initiation of a U.S. multi-site clinical trial evaluating the performance of its T2Resistance ® Panel designed to support a submission to the U.S. Food and Drug Administration (FDA). LEXINGTON, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that its T2SARS-CoV-2™ Panel detects the Omicron COVID-19 variant (B.1.1.529). T2 Biosystems press release (NASDAQ:TTOO): Q4 GAAP EPS of -$0.07 beats by $0.03. LEXINGTON, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced preliminary unaudited financial and operational results for the fourth quarter and full year 2021. The T2Resistance ® Panel, which runs on T2 . Do NOT follow this link! Homepage Membership Levels General Discussion Complete Stock List The book Podcast Membership Data Coverage Founder's Message Free Trial Screeners . --T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the three months ended March 31, 2021.. The statements made herein speak only as of the date of this press release. About T2 Biosystems T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. January 11, 2022 - 9:05 am. This press release contains forward-looking statements within the meaning of the Private Securities . T2 Biosystems Appoints Laura Adams to Its Board of Directors. LEXINGTON, Mass., Feb. 04, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to eighteen new employees. GuruFocus Article or News written by GuruFocusNews and the topic is about: Get Your 7-Day Free Trial! The AP news staff was not involved in its creation. Under the terms of the agreements, T2 Biosystems will sell T2Dx® Instruments, along with . T2 Biosystems Reports Granting of Inducement Award. Press Release: T2 Biosystems to Unveil New Data at September Conferences . McDonough will also serve as a member of the Company's board of directors. The awards were made on January 26, 2022, under the T2 Biosystems' Inducement Award Plan (the "Inducement Plan"), which was adopted on March 1, 2018, and amended and . LEXINGTON, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the three . T2 Biosystems' products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, the T2ResistanceTM Panel, and the T2SARS-CoV-2™ Panel . T2 Biosystems to Report Fourth Quarter and Full Year 2021 Financial Results on February 17, 2022. T2 Biosystems, Inc. yesterday. Recent Highlights The amendment extends both the interest-only period and the maturity date by one year from December 31, 2022 to December 31, 2023. | February 17, 2022 . T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements . All statements contained in . T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. Revenue of $6.98M (-10.3% Y/Y) beats by $1.58M. 01/11/22. T2 Biosystems Announces the Initiation of the T2Biothreat® Panel Clinical Trial . T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients . Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. LEXINGTON, Mass., January 11, 2022 (GLOBE NEWSWIRE)-T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced preliminary unaudited financial and operational results for the fourth quarter and full year 2021. LEXINGTON, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced . --T2 Biosystems, Inc., a global leader in the rapid detection of sepsis-causing pathogens, today announced that its Board of Directors has appointed Aparna Ahuja, MD, as Chief Medical Officer . 02/08/22. T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2021 Results. T2 Biosystems (TTOO): Q1 GAAP EPS of -$0.07.Revenue of $7M (+174.5% Y/Y)Shares+29%AH.Press Release This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. LEXINGTON, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the fourth quarter and full year 2021 after market close on Thursday, February 17, 2022. --T2 Biosystems, Inc., . LEXINGTON, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced preliminary unaudited financial and operational results for the fourth quarter and full year 2021. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Expands International Commercialization with Initial Shipment of T2Dx Instruments to AsiaLEXINGTON, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the . T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most . LEXINGTON, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis . T2 Biosystems, Inc., a company developing the first portable medical diagnostic products which combine nanotechnology and miniaturized magnetic resonance imaging (MRI) technology, today announced the appointment of John McDonough as Chief Executive Officer. T2 Biosystems Announces Fourth Quarter & Full Year 2021 Financial Results Full Year 2021 Total Revenue Growth of 55%; Plans to Double Sepsis Revenue and T2Dx. LEXINGTON, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the execution of territory . Date Title; 01/11/22. All statements contained in this press release that do not relate to matters of historical fact should be . About T2 Biosystems: T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. --T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens, today announced the completion of validation of its COVID-19 molecular diagnostic test, the T2SARS-CoV-2 Panel. T2 Biosystems' products include the T2Dx® Instrument, T2Candida® Panel, and T2Bacteria® Panel, which was recently announced as the first and only in-vitro diagnostic test to receive approval for a New Technology Add-on Payment (NTAP) by CMS, are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to . LEXINGTON, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the execution of territory exclusive distribution agreements in Norway, Finland, and Türkiye. LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the three . We do not undertake, and specifically disclaim, any obligation to update any forward-looking statements contained in this press release. 02/04/22. Find the latest press releases from T2 Biosystems, Inc. Common Stock (TTOO) at Nasdaq.com. LEXINGTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the execution of a territory. The World Health Organization has designated the Omicron variant as a SARS-CoV-2 "variant of concern" with more than 30 mutations in the spike . The company expects FY2022 total revenue of $28M to . T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2021 Results. T2 Biosystems Announces Granting of CE-Mark for T2Resistance™ Panel. Contact us. LEXINGTON, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the successful amendment and extension to its Term Loan Agreement with CRG Servicing LLC ("CRG"). T2 Biosystems: Q4 Earnings Insights 12 Health Care Stocks Moving In Thursday's After-Market Session The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts . $0.39 23:27 21/01/22-1.95%-$0.01. T2 Biosystems' products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, the . The T2Resistance Panel is the only direct-from-blood diagnostic designed to detect genetic markers associated with antibiotic-resistant bloodstream infections. T2 Biosystems 101 Hartwell Avenue Lexington, MA 02421 Phone: 781-457-1200 Fax: 781-357-3080 Toll Free: 877-504-T2T2 (8282) Email Us LEXINGTON, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the initiation of a U.S. multi-site clinical trial evaluating the performance of its T2Resistance ® Panel designed to support a submission to the U.S. Food and Drug Administration (FDA). T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced preliminary unaudited financial and operational results for the fourth quarter and . Recent Highlights (unaudited) T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients . .
What Level Does Heavensward Start, What Is The Best Cut Of Ostrich Meat?, Oven Grilled Chicken Marinade, Winter Jeans Outfits 2020, Fresno Youth Basketball, Perfectly Pink Calendar 2022, Fist Length Beard Islam, Post Acute Navigator Salary, Rachel From Coronation Street,